Skip to main content
. Author manuscript; available in PMC: 2016 Mar 11.
Published in final edited form as: Science. 2014 Nov 14;346(6211):861–865. doi: 10.1126/science.1256999

Fig. 3. Flagellin-mediated protection against RV infection requires both IL-22 and IL-18.

Fig. 3

(A to H) Indicated strains of genetically modified 8-week-old mice were orally inoculated with mouse RV, EC strain. Mice were treated with PBS ± flagellin (20 μg), via intraperitoneal injection, every other day from 0 to 8 days after inoculation. Feces were collected daily and assayed for RV antigens by means of ELISA. The following strain was used in each panel: (A) p40−/−, (B) Rag2/Il2rg−/−, (C) WT C57BL/6 mice treated with IL-17–neutralizing mAb, (D) Il22−/−, (E) WT C57BL/6 mice treated with IL-22–neutralizing mAb, (F) Il1r−/−, (G) IL-18BP TG, and (H) Il18−/− mice. Results in (A) to (H) are shown as mean ± SEM (n = 4 to 6 mice). The difference between mice given PBS and flagellin was statistically significant for (C) and (F) (two-way ANOVA, P < 0.0001) and significant at individual days of (A), (B), (D), (E), (G), and (H) [Student’s t test, P < 0.05 on day 3 in (A), days 7 and 9 of (B), day 5 of (D), day 2 of (E), days 3 and 4 in (G), and days 3 and 4 in (H)].